Arbutus to Participate in Upcoming Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on chronic hepatitis B virus (HBV) and coronavirus therapies, announced participation in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 2, 2021, featuring a fireside chat at 9:00 am ET. Presenters include CEO William Collier and other executives. The second is the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 am ET, also featuring a fireside chat. Links to webcasts are available on their website.
- None.
- None.
WARMINSTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming investor conferences:
Jefferies Virtual Healthcare Conference
- Wednesday, June 2, 2021 at 9:00 am ET (Fireside Chat)
- Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
- Webcast Link
JMP Securities Life Sciences Conference - Virtual
- Thursday, June 17, 2021 at 11:00 am ET (Fireside Chat)
- Presenters: William Collier; Dr. Michael Sofia; Dr. Gaston Picchio; and David Hastings
- Webcast Link
The webcast links for the virtual fireside chats can also be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com
FAQ
What is Arbutus Biopharma's stock symbol?
When is the Jefferies Virtual Healthcare Conference for Arbutus Biopharma?
Who will present at the JMP Securities Life Sciences Conference for ABUS?
Where can I find the webcast links for Arbutus Biopharma's investor conferences?
What is the focus of Arbutus Biopharma's drug development?
